Form 4: Lexeo Therapeutics COO Receives Stock Grant
Insider Transaction (Form 4)
Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics, Inc., reported multiple transactions in common stock on September 24, 2026.
Summary
- Grant/award: acquired 2,110 Common Stock at $2.64 ($5,579) on September 14, 2026; holds 138,288 after (Direct).
- Grant/award: acquired 54,750 Stock Option (right to buy) on September 24, 2026; holds 54,750 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jose Manuel Otero — Officer (Chief Operating Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-14 | Grant/award | Common Stock | 2,110 | $3 | $5.6K | 138,288 |
| 2026-09-24 | Grant/award | Stock Option (right to buy) | 54,750 | — | — | 54,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-14 | Grant/award (2,110 shares) |
| 2026-09-24 | Grant/award (54,750 shares) |
Keywords
insider transaction, Form 4, LXEO, Lexeo Therapeutics, Inc., neutral, Jose Manuel Otero
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.